drugset / Trial / NCT06145178
A Study of Human Cytomegalovirus (HCMV) Vaccine SPYVLP01 With and Without Adjuvants
Non-randomizedSequentialOpen-labelPrevention
Summary
The main purpose of the study is to evaluate the safety and immunogenicity of SPYVLP01 in two different doses with and without adjuvants in healthy adults aged 18-50 years old.
Timeline
- Start
- 2023-11-22
- Primary completion
- 2025-06-20
- Completion
- 2025-07-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SPYVLP01 | Vaccine | — | — |